Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
|Poll|November 18, 2020
Poll: Holiday Stressors
Author(s)Heidi Anne Duerr, MPH, Laurie Martin
What issues do you anticipate your patients will struggle with during the upcoming holidays?
Advertisement
What issues do you anticipate your patients will struggle with during the upcoming holidays?
Advertisement
Related to this article
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Don't miss out on these CME articles! Test your knowledge here.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Relief Is Not Free: A Case Study of Athlete Cannabis Use
4
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
5